T-DXd Shows Significant PFS Improvement in HR+/HER2-Low Breast Cancer
New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.